Liver Diseases  >>  Arlansa (narlaprevir)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Arlansa (narlaprevir) / Merck (MSD)
NCT00689390 / 2006-006529-25: Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)

Checkmark CROI 2014
Mar 2014 - Mar 2014: CROI 2014
Terminated
2/3
1954
NA
Boceprevir, SCH 503034, Narlaprevir, SCH 900518, Peginterferon alfa-2b, PEG-Intron®, SCH 054031, Ribavirin, Rebetol®, Blood/Plasma Collection
Merck Sharp & Dohme LLC
Hepatitis C, Chronic, Hepacivirus
10/14
10/14

Download Options